Sartorius AG · XETR:SRT

Sartorius — 9M 2015 Earnings Presentation

19 slides from Sartorius's earnings presentation, Oct 20, 2015

  1. Slide 1: Conference Call 9M 2015 Results

    Conference Call 9M 2015 Results Joachim Kreuzburg, CEO | October 20, 2015

  2. Slide 2: Disclaimer

    Disclaimer This presentation contains statements concerning the future performance of the Sartorius Group and the Sartorius Stedim Biotech Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarante

  3. Slide 3: Agenda

    Agenda 01 Sartorius Group: 9M 2015 Results | Guidance 2015 02 Sartorius Stedim Biotech Group: 9M 2015 Results | Guidance 2015 03 Questions & Answers

  4. Slide 4: Strong Business Performance Ahead of Expectations

    Strong Business Performance Ahead of Expectations Double-digit growth in order intake, sales revenues and earnings BPS exceeds expectations again driven by sound market growth and ongoing market share gains LPS continues positive development in line with expectations Recent acquisitions performing v

  5. Slide 5: Ongoing Dynamic Growth Across All Lines

    Ongoing Dynamic Growth Across All Lines Sartorius Group 9M 9M Change Change in millions of € unless otherwise specified 2014 1 2015 in cc 2 Order intake 658.1 856.6 30.2 19.9 Sales revenue 645.5 830.3 28.6 18.5 3 Underlying EBITDA 131.9 193.8 46.9 Underlying EBITDA margin in % 20.4 23.3 +2.9 pp Unde

  6. Slide 6: All Regions Report Double-Digit Sales Growth

    All Regions Report Double-Digit Sales Growth Americas EMEA Asia|Pacific Sales by Regions Sales in € million Sales in € million Sales in € million in % 379.0 320.2 EMEA ~ 45% 278.7 172.6 187.7 137.5 Americas ~ 34% € 830.3mn 9M 14 9M 15 9M 14 9M 15 9M 14 9M 15 + 24.2% + 16.8% + 14.7% Asia | Pacific ~

  7. Slide 7: BPS: Growing Beyond Expectations Yet Again

    BPS: Growing Beyond Expectations Yet Again Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +26.5% cc +24.2% cc +54.1% +38.4% +35.9% 637.2 604.3 158.7 460.3 444.7 103.0 26.3% 23.2% 9M 14 9M 15 9M 14 9M 15 9M 14 9M 15  Biopharma market growth stronger t

  8. Slide 8: LPS: Performance in Line with Expectations

    LPS: Performance in Line with Expectations Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +4.6% cc +6.0% cc +21.1% +11.0% +12.5% 219.5 226.0 197.8 200.8 35.1 29.0 15.5% 14.4% 9M 14 9M 15 9M 14 9M 15 9M 14 9M 15  All product lines and regions drive bu

  9. Slide 9: Robust Operating Cash Flow Performance

    Robust Operating Cash Flow Performance Sartorius Group 9M 9M Change  Financial result mainly in millions of € 2014 2015 in % influenced by lower interest Underlying EBITDA 131.9 193.8 46.9 expenses  Reported net profit includes Extraordinary items -4.0 -6.7 -67.4 gain from Intec disposal Financial

  10. Slide 10: All Key Financial Parameters Further Enhanced

    All Key Financial Parameters Further Enhanced Key Financial Indicators Net Debt to Underlying EBITDA Sartorius Group Dec. 31 Sept. 30 3.0 20141 2015 450 Equity ratio in % 39.1 44.9 2.0 300 Net debt in millions of € 335.6 324.1 150 1.0 Net debt | underlying EBITDA 1.7 1.3 0 0.0 1 Including discontinu

  11. Slide 11: Guidance 2015 Revised Upwards

    Guidance 2015 Revised Upwards Previous1 New1 Sales revenue Underlying Sales revenue Underlying growth EBITDA margin growth EBITDA margin Sartorius Group ~12% ~22.5% ~15% ~23.0% Bioprocess Solutions ~15% ~25.5% ~20% ~26.0% Lab Products & Services ~5% ~15.5% ~5% ~15.5% 1 In constant currencies  Expec

  12. Slide 12: Agenda

    Agenda 01 Sartorius Group: 9M 2015 Results | Guidance 2015 02 Sartorius Stedim Biotech Group: 9M 2015 Results | Guidance 2015 03 Questions & Answers

  13. Slide 13: Double-digit Growth Ahead of Expectations

    Double-digit Growth Ahead of Expectations Sartorius Stedim Biotech 9M 9M Change Change in millions of € unless otherwise specified 2014 2015 in cc Order intake 509.7 694.0 36.2 24.9 Sales revenue 494.3 660.9 33.7 22.7 Underlying EBITDA 114.0 173.2 51.9 Underlying EBITDA margin in % 23.1 26.2 +3.1 pp

  14. Slide 14: Excellent Performance Driven by All Regions

    Excellent Performance Driven by All Regions Americas EMEA Asia|Pacific Sales by Regions Sales in € million Sales in € million Sales in € million in % 299.5 242.4 240.7 EMEA ~ 45% 157.2 119.0 96.4 Americas ~ 37% € 660.9mn 9M 14 9M 15 9M 14 9M 15 9M 14 9M 15 + 28.8% + 22.2% + 13.8% Asia | Pacific ~ 18

  15. Slide 15: Significant Increase in Operating Cash Flow

    Significant Increase in Operating Cash Flow Sartorius Stedim Biotech Group 9M 9M Change  Financial result influenced by in millions of € 2014 2015 lower interest expenses and on Underlying EBITDA 114.0 173.2 51.9 the contrary by valuation effects of derivatives |fx loans - mainly Extraordinary item

  16. Slide 16: Financial Position Remained Strong

    Financial Position Remained Strong Key Financial Indicators Net Debt to Underlying EBITDA Sartorius Stedim Biotech Dec. 31 Sept. 30 2014 2015 150 2.0 Equity ratio in % 59.4 59.4 1.5 100 1.0 Net debt in millions of € 87.4 108.9 50 0.5 Net debt | underlying EBITDA 0.5 0.5 0 0.0 Q1-Q4 Q1-Q4 Q1-Q4 Q1-Q4

  17. Slide 17: Guidance 2015 Upgraded

    Guidance 2015 Upgraded Previous 1 New1 Sales revenue growth ~15% ~20% Underlying EBITDA margin ~25.0 - 25.5% ~25.5 - 26.0% 1 In constant currencies  Expected growth contribution of ~1.5 pp from recent acquisitions  Capex ratio ~6% - 8% 17

  18. Slide 18: Agenda

    Agenda 01 Sartorius Group: 9M 2015 Results | Guidance 2015 02 Sartorius Stedim Biotech Group: 9M 2015 Results | Guidance 2015 03 Questions & Answers

  19. Slide 19: Thank you very much for your attention

    Thank you very much for your attention

Sartorius — 9M 2015 Earnings Presentation on 6ix